| abstract |
The present invention provides a depot formulation designed to minimize changes in plasma concentration after dosing for use in psychotic therapies dependent on small molecule drugs and other forms of treatment. A polymer based on lactic acid or lactic acid and glycolic acid having a monomer ratio of lactic acid to glycolic acid ranging from 100: 0 to 15:85 and having a number average molecular weight ranging from 1,000 to 30,000 5 to 80% by weight of the biocompatible polymer, which is a copolymer based on the total weight of the vehicle, and 20 to 95% of the organic solvent blended with the biocompatible polymer to form a viscous gel, based on the total weight of the vehicle. A vehicle containing 1% by weight, and a small molecule drug selected from an antipsychotic and its salt form, incorporated into a viscous gel and having a particle form with an average particle size in the range of 0.1-125 μm. An injectable depot formulation containing 1 to 50% by weight based on the total weight. [Selection] Figure 4 |